Project Grant P60AA032176
- This $634,829 Project Grant award from the Department of Health and Human Services National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) supports a research project titled "Geroprotective Precision Medicine Strategies in PWH that Use Alcohol". The project aims to identify personalized approaches to overcoming inconsistent responses to microbiota-targeted interventions and validate their capacity to offset mechanisms of biological aging in people with...
- The Aging Well with HIV through Alcohol Research and Risk Reduction and Education (AWAR3E) Center is a $1,493,442 Project Grant awarded by the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs) on September 10, 2025. The grant supports a collaborative research initiative across four HIV cohorts to characterize "inflammaging" and associated geriatric syndromes among people with HIV. The Center will investigate novel biomarkers of inflammaging,...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,593,618 Project Grant under the Alcohol Research Programs (CFDA 93.273) to establish the Center for Alcohol/HIV Innovations and Biomarker Research (CALIBER) at the University of California, San Francisco (UCSF). The goal of CALIBER is to (1) reduce the harmful effects of alcohol use on HIV prevention and HIV-associated comorbidities, (2) advance innovations in alcohol measurement, and (3) train the next generation of...
- This Project Grant award of $123,045.00 from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) supports research on the role of the TRAF3IP2 protein in the development of alcohol-related cardiomyopathy. The project will investigate whether alcohol-induced cardiac fibroblast activation, proinflammatory cytokine expression, and extracellular matrix changes are dependent on TRAF3IP2, and whether deleting the TRAF3IP2 gene prevents alcohol-induced...
- The Project Grant award "CENTERING HIV STIGMA IN CLINICAL CONVERSATIONS TO INCREASE ALCOHOL TREATMENT UPTAKE (CHAT)" is funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The key objectives of this $179,959 award, with a project period from September 1, 2025 to August 31, 2030, are to: 1) characterize patient and provider perspectives on experiences of stigma and preferences for using patient-reported stigma...
- This Project Grant award, totaling $755,539, was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The funding will support research conducted by Emory University to evaluate the real-world utilization, effectiveness, and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a treatment for alcohol use disorder (AUD). The project aims to leverage administrative claims data and linked electronic health records...
- This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under CFDA 93.273 - Alcohol Research Programs provides $603,499.00 to the University of Texas Health Science Center at Houston (UTHealth) to develop a comprehensive, web-based knowledge module that integrates microbiota, metabolite, and host pathway data to map microbial signatures and mechanisms involved in alcohol-related organ damage (AROD). The project aims to define "alcohol enterotypes"...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $105,132 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Kentucky Research Foundation. The grant, titled "Uncovering the Functional and Mechanistic Dysregulation of Monocytes After Abstinence and Post-Abstinence Drinking," will leverage a rhesus macaque model to investigate the persistent functional, transcriptional, and epigenetic changes in peripheral monocytes induced by...
- The Project Grant award of $131,654 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) is funding the development of a Lactobacillus-vectored alkaline phosphatase (AP) to mitigate alcohol-induced leaky gut and lipopolysaccharide (LPS) endotoxin load in the gut. The project aims to apply a two-pronged approach using: 1) Lactobacillus-based drug delivery technology to prevent alcohol-induced gut leakiness, and 2) the delivery of...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $404,250 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Tennessee Health Science Center. The grant, awarded on September 23, 2025 with an ultimate completion date of August 31, 2027, supports research to explore the role of margaric acid in alcohol-associated liver diseases (AALD). The project aims to determine if margaric acid supplementation can attenuate alcohol-induced gut and liver...
The Southeast Translational Alcohol and HIV Research (STAHR) Center was awarded a $1,785,057 Project Grant by the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) to conduct three inter-related clinical trials and observational studies focused on reducing alcohol consumption and mitigating alcohol's harmful effects on cardiovascular disease risk among people living with HIV. The key objectives are to: 1) examine the association between alcohol, gut dysbiosis, inflammation, and cardiovascular disease risk, and determine if a probiotic can increase endogenous GLP-1 levels; 2) determine the association between dysregulation of tryptophan catabolism and its metabolites with alcohol, senescent T cells, vascular inflammation, and cardiovascular disease, and whether a probiotic can reduce these effects; and 3) test if a GLP-1 receptor agonist decreases alcohol consumption, smoking, and cardiovascular disease risk among people living with HIV. The award period runs from August 11, 2025 through July 31, 2030, and the research will be conducted at Vanderbilt University Medical Center.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.8m | 8/6/25 |